{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:10:10Z","timestamp":1793653810396,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although therapeutic options for hidradenitis suppurativa (HS) continue to expand, unmet needs remain substantial. We evaluated the efficacy and safety of povorcitinib (an oral, highly selective Janus kinase 1 (JAK1) inhibitor) in patients with moderate to severe HS in two randomized trials. STOP-HS1 and STOP-HS2 were identically designed, randomized, double-blind, placebo-controlled phase 3 trials. Adults with moderate to severe HS were randomized 2:2:1:1 to once-daily treatment through week 54: povorcitinib 45\u2009mg; povorcitinib 75\u2009mg; placebo with crossover at week 12 to povorcitinib 45\u2009mg; or placebo with crossover at week 12 to povorcitinib 75\u2009mg. The primary endpoint was HiSCR50 (\u226550% decrease in total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count) at week 12. STOP-HS1\/STOP-HS2 enrolled 608\/619 patients, respectively. In both studies, both povorcitinib doses met the primary endpoint; in STOP-HS1, 82\/204 (40%) patients in the povorcitinib 45-mg group and 82\/202 (41%) in the 75-mg group versus 60\/202 (30%) in the placebo group achieved HiSCR50 (OR (95% CI) 45\u2009mg: 1.6 (1.1\u22122.5),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0240; 75\u2009mg: 1.6 (1.1\u22122.4),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0214); corresponding values for STOP-HS2 were 88\/208 (42%) and 88\/208 (42%) versus 58\/203 (29%; OR (95% CI) 45\u2009mg: 1.8 (1.2\u22122.8),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0035; 75\u2009mg: 1.9 (1.2\u22122.8);\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0033). Through week 12, across STOP-HS1\/STOP-HS2, serious treatment-emergent adverse events (AEs) occurred in 1\u22122% of patients across povorcitinib doses and in 2\u22123% with placebo; through week 54, serious AEs occurred in 5%\/6% of patients receiving 45-mg\/75-mg povorcitinib, respectively. The most frequent AEs among patients treated with 45-mg\/75-mg povorcitinib were acne (17%\/20%), nasopharyngitis (10%\/12%) and upper respiratory tract infection (11%\/10%). One death of undetermined etiology was reported and deemed unrelated to treatment. No new or unexpected safety findings were identified. Oral povorcitinib demonstrated significant improvements in HiSCR50 versus placebo and a favorable safety profile in patients with moderate to severe HS. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/search?term=NCT05620823&amp;viewType=Card\" ext-link-type=\"uri\">NCT05620823<\/jats:ext-link>\n                    and\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/search?term=NCT05620836&amp;viewType=Card\" ext-link-type=\"uri\">NCT05620836<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04534-z","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:05:41Z","timestamp":1784797541000},"page":"3071-3081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials"],"prefix":"10.1038","volume":"32","author":[{"given":"Martina L.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-1590","authenticated-orcid":false,"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Lev-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Reguia\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel H.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2258-8357","authenticated-orcid":false,"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay S.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn S.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"4534_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat, R. et al. Hidradenitis suppurativa. Lancet 405, 420\u2013438 (2025).","journal-title":"Lancet"},{"key":"4534_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis, C. C. et al. What causes hidradenitis suppurativa?\u201415 years after. Exp. Dermatol. 29, 1154\u20131170 (2020).","journal-title":"Exp. Dermatol."},{"key":"4534_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","volume":"36","author":"JR Ingram","year":"2022","unstructured":"Ingram, J. R. et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J. Eur. Acad. Dermatol. Venereol. 36, 1597\u20131605 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"4534_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/jamadermatol.2025.2373","volume":"161","author":"D Bouazzi","year":"2025","unstructured":"Bouazzi, D. et al. Prevalence of hidradenitis suppurativa: a meta-analysis of Global Hidradenitis Suppurativa Atlas studies. JAMA Dermatol. 161, 1022\u20131028 (2025).","journal-title":"JAMA Dermatol."},{"key":"4534_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jaad.2024.09.008","volume":"91","author":"S Daveluy","year":"2024","unstructured":"Daveluy, S. & Okoye, G. A. Quality of life and the patient journey in hidradenitis suppurativa. J. Am. Acad. Dermatol. 91, S8\u2013S11 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"4534_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","volume":"149","author":"KR van Straalen","year":"2022","unstructured":"van Straalen, K. R., Prens, E. P. & Gudjonsson, J. E. Insights into hidradenitis suppurativa. J. Allergy Clin. Immunol. 149, 1150\u20131161 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"4534_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/der2.126","volume":"3","author":"MM Stokes","year":"2022","unstructured":"Stokes, M. M. & Holahan, H. M. Comorbidities present in hidradenitis suppurativa. Dermatol. Rev. 3, 58\u201364 (2022).","journal-title":"Dermatol. Rev."},{"key":"4534_CR8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/jcm14041110","volume":"14","author":"TZ Rohan","year":"2025","unstructured":"Rohan, T. Z., Hafer, R., Duong, T., Dasgupta, R. & Yang, S. Hidradenitis suppurativa is associated with an increased risk of adverse cardiac events and all-cause mortality. J. Clin. Med. 14, 1110 (2025).","journal-title":"J. Clin. Med."},{"key":"4534_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/pharmaceutics14010044","volume":"14","author":"VA Zouboulis","year":"2021","unstructured":"Zouboulis, V. A., Zouboulis, K. C. & Zouboulis, C. C. Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing-a molecular meta-analysis. Pharmaceutics 14, 44 (2021).","journal-title":"Pharmaceutics"},{"key":"4534_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"C Zouboulis","year":"2025","unstructured":"Zouboulis, C. et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J. Eur. Acad. Dermatol. Venereol. 39, 899\u2013941 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"4534_CR11","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s13555-025-01487-y","volume":"15","author":"A Garg","year":"2025","unstructured":"Garg, A., Hsiao, J., Porter, M. L. & Shi, V. Current treatments and future directions for hidradenitis suppurativa: a narrative review of completed and ongoing phase 3 clinical trials of biologic therapies. Dermatol. Ther. (Heidelb.) 15, 2361\u20132377 (2025).","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"4534_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball, A. B. et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N. Engl. J. Med. 375, 422\u2013434 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4534_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball, A. B. et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401, 747\u2013761 (2023).","journal-title":"Lancet"},{"key":"4534_CR14","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball, A. B. et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 403, 2504\u20132519 (2024).","journal-title":"Lancet"},{"key":"4534_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jaad.2024.03.028","volume":"91","author":"JP Pham","year":"2024","unstructured":"Pham, J. P. et al. Drug survival of biologics in hidradenitis suppurativa: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 91, 170\u2013172 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"4534_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/13696998.2023.2194804","volume":"26","author":"D Willems","year":"2023","unstructured":"Willems, D. et al. A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. J. Med. Econ. 26, 503\u2013508 (2023).","journal-title":"J. Med. Econ."},{"key":"4534_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40257-024-00871-2","volume":"25","author":"CB Dagenet","year":"2024","unstructured":"Dagenet, C. B. et al. Adherence to hidradenitis suppurativa treatment. Am. J. Clin. Dermatol. 25, 585\u2013594 (2024).","journal-title":"Am. J. Clin. Dermatol."},{"key":"4534_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger, J. G. et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br. J. Dermatol. 190, 149\u2013162 (2024).","journal-title":"Br. J. Dermatol."},{"key":"4534_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen, A. et al. JAK inhibitor selectivity: new opportunities, better drugs? Nat. Rev. Rheumatol. 20, 649\u2013665 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4534_CR20","doi-asserted-by":"publisher","first-page":"12830","DOI":"10.1021\/acs.jmedchem.5c03753","volume":"69","author":"J Zhuo","year":"2026","unstructured":"Zhuo, J. et al. Discovery of the orally bioavailable isoform selective Janus kinase 1 (JAK1) compound povorcitinib (INCB054707) for the treatment of inflammatory and autoimmune diseases. J. Med. Chem. 69, 12830\u201312852 (2026).","journal-title":"J. Med. Chem."},{"key":"4534_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby, J. S. et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. 90, 521\u2013529 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"4534_CR22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/jdv.20550","volume":"39","author":"JR Ingram","year":"2025","unstructured":"Ingram, J. R. et al. Hidradenitis suppurativa with and without draining tunnels: a real-world study characterizing differences in treatment and disease burden. J. Eur. Acad. Dermatol. Venereol. 39, 1431\u20131441 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"4534_CR23","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"\u0141 Matusiak","year":"2020","unstructured":"Matusiak, \u0141 Profound consequences of hidradenitis suppurativa: a review. Br. J. Dermatol. 183, e171\u2013e177 (2020).","journal-title":"Br. J. Dermatol."},{"key":"4534_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese, C. A., Moltrasio, C., Genovese, G. & Marzano, A. V. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Exp. Rev. Clin. Immunol. 20, 525\u2013545 (2024).","journal-title":"Exp. Rev. Clin. Immunol."},{"key":"4534_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","volume":"158","author":"S Der Sarkissian","year":"2022","unstructured":"Der Sarkissian, S. et al. Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review. JAMA Dermatol. 158, 300\u2013313 (2022).","journal-title":"JAMA Dermatol."},{"key":"4534_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843\u2013862 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4534_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg, A. et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J. Am. Acad. Dermatol. 86, 1092\u20131101 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"4534_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2397477","volume":"35","author":"BL Chen","year":"2024","unstructured":"Chen, B. L. et al. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis. J. Dermatolog. Treat. 35, 2397477 (2024).","journal-title":"J. Dermatolog. Treat."},{"key":"4534_CR29","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke, B., Yates, M., Adas, M., Bechman, K. & Galloway, J. The safety of JAK-1 inhibitors. Rheumatology (Oxford) 60, ii24\u2013ii30 (2021).","journal-title":"Rheumatology (Oxford)"},{"key":"4534_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel, C., Cornman, H., Kambala, A. & Kwatra, S. G. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol. Ther. (Heidelb.) 13, 729\u2013749 (2023).","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"4534_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves, P. G. et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann. Rheum. Dis. 80, 865\u2013875 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"4534_CR32","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/bjd\/ljae238","volume":"192","author":"JW Frew","year":"2025","unstructured":"Frew, J. W. Unravelling the complex pathogenesis of hidradenitis suppurativa. Br. J. Dermatol. 192, i3\u2013i14 (2025).","journal-title":"Br. J. Dermatol."}],"updated-by":[{"DOI":"10.1038\/s41591-026-04747-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04534-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:46Z","timestamp":1793035906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04534-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4534"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04534-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04747-2","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04747-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.P. has served as a consultant for AbbVie, Almirall, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Eli Lilly, Framework for Interoperable Data Exchange (FIDE), Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, Trifecta Clinical\/WCG, UCB and Zura Bio and as an investigator for AbbVie, AnaptysBio, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Bayer, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, OASIS Pharmaceuticals, Otsuka, Pfizer, Prometheus, Propeller Biosciences, Regeneron, Sanofi, Sonoma Biotherapeutics, UCB and Zura Bio. She has received royalties from Beth Israel Deaconess Medical Center and fellowship funding to the institution from AbbVie. A.M. has acted as a consultant, advisory board member and investigator for and received honoraria from AbbVie, Acelyrin, Amgen, Boehringer Ingelheim, Incyte, Johnson & Johnson, Legit Health, LEO Pharma, Eli Lilly, L\u2019Oreal, MoonLake Immunotherapeutics, MSD, Novartis, Sandoz, Sanofi, Takeda and UCB. C.J.S. has acted as an investigator for AbbVie, AstraZeneca, ChemoCentryx, GlaxoSmithKline, Incyte, InflaRx, Novartis and UCB; reports consultancy fees from AbbVie, Alumis, AstraZeneca, InflaRx, Incyte, Logical Images, Oruka Therapeutics, Sonoma Biotherapeutics and UCB; and has acted as a speaker for AbbVie and Novartis. F.G.B. has received honoraria for participation in advisory boards, in clinical trials and\/or as a speaker from AbbVie, AbbVie Deutschland GmbH & Co. KG, Acelyrin, Almirall, Avalo, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Citryll, Incyte, Inflax, Janssen-Cilag GmbH, Johnson & Johnson, Eli Lilly, Merck, M\u00f6lnlycke, MoonLake Immunotherapeutics, Navigator Medicines, Novartis, Sanofi, Sitala, Takeda and UCB. H.L.-T. is the founder, owns stock in and has a podcast for Learnskin.com; has served as a consultant for Hidramed Solutions, Insmed, MoonLake Immunotherapeutics, Next Science, Novartis and UCB; has been a speaker for Incyte and UCB; has participated in trials for Incyte, Eli Lilly, Medline, M\u00f6lnlycke, MoonLake Immunotherapeutics, Novartis, Sigvaris, Solascure, Tissue Tech and UCB; has received research support from Essity, Next Science, Sigvaris and Vomaris; and is a Q10 Board of Directors member for the HS Foundation. J.L.H. is on the board of directors of the Hidradenitis Suppurativa Foundation and has served as an advisor, investigator and\/or speaker for AbbVie, Amgen, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Insmed, LEO Pharma, MoonLake Immunotherapeutics, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Regeneron, Sanofi, Spyre Therapeutics and UCB. J.W.F. has conducted advisory work for Janssen, Boehringer Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, ChemoCentryx, AbbVie, Azora, Novartis and UCB; has participated in trials for Pfizer, UCB, Boehringer Ingelheim, Eli Lilly, CSL Behring and Azora; and has received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche-Posay. Z.R. has received honoraria (investigator\/speaker or advisory boards) from AbbVie, Almirall, Alumis, Amgen, Bayer, Boehringer Ingelheim, Celltrion, Incyte, Galderma, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Regeneron, Sanofi and UCB. M.J.G. is an investigator, speaker and\/or advisor for AbbVie, Akros, Alumis, Amgen, AnaptysBio, Arcutis, Aristea, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, MoonLake Immunotherapeutics, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Sun Pharma, Takeda, Tarsus, UCB, Union, Vyne and Vyntex. N.G. has participated in clinical trials with AbbVie, Pfizer, ChemoCentryx and Incyte; served on advisory boards and consulted for Novartis, Boehringer Ingelheim, Sonoma Biotherapeutics, UCB and MoonLake Immunotherapeutics; received research support from Novartis and DeepX Health; and currently serves on the board of directors for the HS Foundation. H.H.v.d.Z. has received consultancy fees and lecture honoraria from AbbVie, Incyte, InflaRx, Insmed, Novartis and UCB. V.d.M. has no conflicts of interest to declare. A.V.M. reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. B.D.E. has served as a speaker, advisor and\/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Celldex, Concert, Dermavant, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, LEO Pharma, Merck, Navigator Medicines, Novartis, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB and Ventyx. L.S.A. has served as a speaker, advisor and\/or investigator for AbbVie, Alumis, Amgen, Apollo Therapeutics, arGEN-X, AstraZeneca, Biofrontera AG, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, ChemoCentryx, CorEvitas, Corrona, DermTech International, Eli Lilly, Exact Sciences, GlaxoSmithKline Immunology, Helsinn Healthcare, IgGenix, Incyte, Janssen, Kymera Therapeutics, Kyowa Kirin, LEO Pharma, Lilly ICOS, Merck, Mindera, Novartis, Pfizer, Regeneron, Replimune, Sanofi, Soligenix, Sun Pharma, Takeda, Timber Pharmaceuticals, Trevi Therapeutics, UCB, VeraDermics and Zura Bio. K.H. reports consultancy\/advisory board honoraria from AbbVie, Boehringer Ingelheim, Novartis and Sanofi. He has received speaker fees\/grants from AbbVie, Boehringer Ingelheim, Eisai, Novartis, Sanofi and UCB. C.T., J.K., H.Z., J.S.K., K.B. and L.L.S. are employees and shareholders of Incyte. C.C.Z. reports consultancy\/advisory board disease-relevant honoraria from Almirall, Boehringer Ingelheim, Eli Lilly, Idorsia, Incyte, MSD, Novartis, Pfizer, Sanofi, Takeda, UCB and Zura Bio. He has received speaker fees from Bristol Myers Squibb, Novartis and UCB; is president of the EHSF e.V., coordinator of the ALLOCATE Skin group of the ERN Skin and chair of the ARHS Task Force group of the EADV; is editor of EADV News; and is co-copyright holder of IHS4 on behalf of the EHSF e.V.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}